Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.071
Sell
RSI(14)
27.544
Sell
STOCH(KDJ)(9,3,3)
17.730
Sell
ATR(14)
0.103
High Vlolatility
CCI(14)
-257.847
Oversold
Williams %R
99.863
Oversold
TRIX(12,20)
0.021
Sell
StochRSI(14)
0.000
Oversold
Search
aTyr Pharma Inc
ATYRAdd to Watchlist
0.560USD
+0.164+41.42%
Close 05/14, 16:00（ET）Quotes delayed by 15 min
54.89MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of aTyr Pharma Inc
Currency: USD Updated: 2026-05-13Key Insights
aTyr Pharma Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 126 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.36.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
aTyr Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
aTyr Pharma Inc Highlights
StrengthsRisks
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Growing
The company is in a growing phase, with the latest annual income totaling USD 190.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 190.00K.
Overvalued
The company’s latest PE is -0.50, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.62M shares, decreasing 28.92% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 1.11K shares of this stock.
Analyst Rating
Based on
9
analysts
Hold
Current Rating
6.357
Target Price
+569.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-13The current financial score of aTyr Pharma Inc is 6.90, ranking 165 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
5.96
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.86
Operational Efficiency
3.14
Growth Potential
10.00
Shareholder Returns
7.54
aTyr Pharma Inc's Company Valuation
Currency: USD Updated: 2026-05-13The current valuation score of aTyr Pharma Inc is 7.36, ranking 122 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.50, which is 0.00% below the recent high of -0.50 and -1579.61% above the recent low of -8.34.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 126/383
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-13The current earnings forecast score of aTyr Pharma Inc is 6.80, ranking 324 out of 383 in the Biotechnology & Medical Research industry. The average price target is 1.00, with a high of 20.00 and a low of 1.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Hold
Current Rating
6.357
Target Price
+569.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
aTyr Pharma Inc
ATYR
9
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-13The current price momentum score of aTyr Pharma Inc is 6.58, ranking 245 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.83 and the support level at 0.18, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.749
Sell
MA10
0.811
Sell
MA20
0.812
Sell
MA50
0.826
Sell
MA100
0.826
Sell
MA200
1.561
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-13Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-13The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of aTyr Pharma Inc is 3.26, ranking 151 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.60
VaR
+6.15%
240-Day Maximum Drawdown
+94.01%
240-Day Volatility
+187.97%
Return
Best Daily Return
60 days
+23.49%
120 days
+26.16%
5 years
+66.97%
Worst Daily Return
60 days
-44.20%
120 days
-44.20%
5 years
-83.17%
Sharpe Ratio
60 days
-1.69
120 days
-0.34
5 years
-0.01
Risk Assessment
Maximum Drawdown
240 days
+94.01%
3 years
+94.01%
5 years
+96.83%
Return-to-Drawdown Ratio
240 days
-0.96
3 years
-0.29
5 years
-0.19
Skewness
240 days
-4.07
3 years
-3.56
5 years
-1.22
Volatility
Realised Volatility
240 days
+187.97%
5 years
+109.04%
Standardised True Range
240 days
+54.14%
5 years
+54.78%
Downside Risk-Adjusted Return
120 days
-39.78%
240 days
-39.78%
Maximum Daily Upside Volatility
60 days
+78.18%
Maximum Daily Downside Volatility
60 days
+110.25%
Liquidity
Average Turnover Rate
60 days
+1.49%
120 days
+2.00%
5 years
--
Turnover Deviation
20 days
-44.37%
60 days
-54.12%
120 days
-38.65%
Peer Comparison
Biotechnology & Medical Research
aTyr Pharma Inc
ATYR
6.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
